AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 152 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $45,178 | +101.7% | 2,986 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $22,395 | -17.6% | 2,986 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $27,173 | -67.0% | 2,986 | -74.6% | 0.00% | 0.0% |
| Q4 2021 | $82,450 | -38.6% | 11,745 | -0.3% | 0.00% | -50.0% |
| Q3 2021 | $134,315 | -28.8% | 11,782 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $188,630 | -4.6% | 11,782 | +6.4% | 0.00% | 0.0% |
| Q1 2021 | $197,821 | +19.9% | 11,070 | -9.3% | 0.00% | +50.0% |
| Q4 2020 | $164,971 | +7.7% | 12,211 | -6.1% | 0.00% | -33.3% |
| Q3 2020 | $153,128 | -26.2% | 13,010 | -7.5% | 0.00% | -25.0% |
| Q2 2020 | $207,585 | +9.3% | 14,064 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $189,864 | -44.1% | 14,064 | 0.0% | 0.00% | -33.3% |
| Q4 2019 | $339,927 | +25.8% | 14,064 | 0.0% | 0.01% | +20.0% |
| Q3 2019 | $270,310 | -24.5% | 14,064 | +16.2% | 0.01% | -16.7% |
| Q2 2019 | $357,791 | -34.9% | 12,108 | +4.6% | 0.01% | -40.0% |
| Q1 2019 | $549,860 | +31.6% | 11,576 | 0.0% | 0.01% | +25.0% |
| Q4 2018 | $417,894 | -41.3% | 11,576 | 0.0% | 0.01% | -38.5% |
| Q3 2018 | $712,503 | -99.9% | 11,576 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $781,959,000 | +34.7% | 11,576 | +8.2% | 0.01% | +62.5% |
| Q1 2018 | $580,421,000 | +91884.3% | 10,699 | +1.4% | 0.01% | 0.0% |
| Q4 2017 | $631,000 | -40.6% | 10,555 | -51.7% | 0.01% | +14.3% |
| Q3 2017 | $1,062,000 | -2.5% | 21,844 | +5.4% | 0.01% | -12.5% |
| Q2 2017 | $1,089,000 | +15.9% | 20,721 | 0.0% | 0.01% | +14.3% |
| Q1 2017 | $940,000 | +19.9% | 20,721 | 0.0% | 0.01% | +16.7% |
| Q4 2016 | $784,000 | +16.1% | 20,721 | +15.8% | 0.01% | +20.0% |
| Q3 2016 | $675,000 | +114.3% | 17,893 | 0.0% | 0.01% | +150.0% |
| Q2 2016 | $315,000 | +68.4% | 17,893 | +16.6% | 0.00% | +100.0% |
| Q1 2016 | $187,000 | -50.0% | 15,349 | 0.0% | 0.00% | -66.7% |
| Q4 2015 | $374,000 | +37.5% | 15,349 | 0.0% | 0.00% | +50.0% |
| Q3 2015 | $272,000 | +0.4% | 15,349 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $271,000 | +2.7% | 15,349 | +70.0% | 0.00% | 0.0% |
| Q4 2014 | $264,000 | +41.2% | 9,028 | 0.0% | 0.00% | +100.0% |
| Q3 2014 | $187,000 | -11.8% | 9,028 | +5.5% | 0.00% | 0.0% |
| Q2 2014 | $212,000 | – | 8,558 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |